Targeting IL ‐23 in Generalized Pustular Psoriasis: Clinical Success With Guselkumab in an Elderly Patient With Comorbidities

Documenti analoghi

• Guselkumab Is Effective for the Management of Scalp Psoriasis in Both Biologic‐Naïve and Biologic‐Experienced Patients: Results From a Real‐World, Retrospective Study
  di: Ioannis‐Alexios Koumprentziotis, et al.
  Pubblicazione: (2025)
• Switching within the class of IL‐23 inhibitors for the treatment of psoriasis: A systematic review
  di: Ioannis‐Alexios Koumprentziotis, et al.
  Pubblicazione: (2025)
• Single‐center experience with bimekizumab in psoriasis patients with previous exposure to interleukin‐17 inhibitors
  di: Ioannis‐Alexios Koumprentziotis, et al.
  Pubblicazione: (2024)
• Low Awareness of Small Diameter and the ABCDE Rule for Melanoma Self‐Detection: A Survey‐Based Study
  di: Clio Dessinioti, et al.
  Pubblicazione: (2025)
• Dual Immune‐Related Toxicities: Secukinumab‐Induced Bullous Pemphigoid Following ICI ‐Associated Psoriasis in a Cancer Patient
  di: Ioanna A. Paschou, et al.
  Pubblicazione: (2025)